Clinical trials: Atypical Nevus
Clinically Atypical Pigmented Skin Lesion
MelaFind Evaluations for Patients With Multiple Nevi
We have added objectives 4-6 to our updated study: Study Objective 1: To determine whether the distribution of MelaFind scores is different for different patients with multiple nevi, and whether such distributions can be utilized…
- Trial name
- NCT01700101
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Malignant Skin Neoplasm
At-Home Dermoscopy Artificial Intelligence
This is a new protocol to analyze how the use of the Sklip System enables laypersons to safely triage self-selected pigmented skin lesions of concern (PSLCs) from home with the same or better accuracy than pre-specified…
- Trial name
- NCT05321784
- Testing
- Dermoscopy, Digital Photography, Self-Skin Examination
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Basal Cell Carcinoma, Squamous Cell Carcinoma
Photochemical Tissue Bonding
The broad aim of this study is to evaluate the efficacy of photochemical tissue bonding (PTB) for the closure of skin excisions.
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevus
- Trial name
- PTB (NCT00586040)
- Testing
- tissue bonding, sutures
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Melanoma, Melanoma in Situ
BioMEL- Diagnostic and Prognostic Factors in Melanoma.
The investigators' hypothesis is that cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi all differ in not only clinical characteristics but also molecular and genotypic characteristics.
- Conditions
- Melanoma, Melanoma in Situ, Dysplastic Nevi, Mole (Dermatology)
- Trial name
- BioMEL (NCT05446155)
- Testing
- Imaging
- Where
- 4 sites in Sweden
- Volunteers
- 2,000 people
- Sponsor
- Region Skane
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS)
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
- Conditions
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier
- Trial name
- CAPS5 (NCT02000089)
- Testing
- Secretin, MRI, Tumor marker gene test with CA19-9
- Where
- 9 sites in United States
- Volunteers
- 9,000 people
- Sponsor
- Johns Hopkins University
Melanoma
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of…
- Trial name
- NCT06599619
- Testing
- Single agent, adjuvant anti-PD1 therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Kirkwood
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
This phase II trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors…
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm
- Trial name
- NCT07621614
- Testing
- Biospecimen Collection, Chest Radiography, Computed Tomography
- Where
- 13 sites in United States
- Volunteers
- 51 people
- Sponsor
- Children's Oncology Group
Melanoma, Dysplastic Nevi
Family Study of Melanoma in Italy
During the course of a case-control study of melanoma conducted at the Bufalini Hospital, Cesena, Italy in the years 1994-1996, 20 families with 2 or 3 melanoma cases were identified and studied.
- Conditions
- Melanoma, Dysplastic Nevi, Melanocytic Nevi
- Trial name
- NCT00339222
- Where
- 7 sites in Italy, Spain
- Volunteers
- 1,708 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Segmental Dysplastic Nevi
Genetic Identification (ID) of Segmental Dysplastic Nevi
The investigators' goal is to identify the mutation in the gene that is responsible for the development of segmental dysplastic nevi. To identify the gene the investigators may use a candidate gene approach (i.e.
- Trial name
- NCT00955578
- Testing
- Punch Biopsy
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8
- Trial name
- NCT07040280
- Testing
- Biopsy Procedure, Biospecimen Collection, Sulforaphane
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanocytic Nevi, Melanoma (Skin Cancer)
Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions
This observational, prospective cohort study aims to evaluate the diagnostic relevance of Reflectance Confocal Microscopy (RCM) features in atypical melanocytic lesions scheduled for surgical excision, and to correlate these…
- Conditions
- Melanocytic Nevi, Melanoma (Skin Cancer), Next Generation Sequencing (NGS)
- Trial name
- NCT07277920
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Modena and Reggio Emilia
Melanoma, Dysplastic Nevus Syndrome
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.
- Trial name
- NCT00040352
- Where
- 2 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Pancreas Cancer
Pancreatic Cancer Early Detection Program
Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer
- Trial name
- PCEDP (NCT02206360)
- Testing
- Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- White Plains Hospital
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Dysplastic Nevus Syndrome
Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)
The purpose of this study is to evaluate the safety and effectiveness of an experimental 20% betulinic acid ointment (BA ointment) as a treatment for dysplastic nevi with the potential to transform into melanoma.
- Trial name
- NCT00346502
- Testing
- 20% betulinic acid ointment, BA
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Nevi, Dysplastic
INTER-PATHOLOGIST READER STUDY
This is a post study histology analysis from previously obtained pathology slides.
- Trial name
- NCT06246903
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Orlucent, Inc
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals